Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JAMA Oncology
|
February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial
Anand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Nature Communications
|
September 18, 2024
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia
Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, et al.
Future Oncology (London, England)
|
July 11, 2026
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed <i>FLT3</i>-ITD-negative acute myeloid leukemia
Pau Montesinos, Jessica K Altman, Lars Bullinger, et al.
Haematologica
|
August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
Sabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
The Lancet. Oncology
|
June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E Perl, Jessica K Altman, Jorge Cortes, et al.
American Journal of Hematology
|
January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology
|
June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Transplantation and Cellular Therapy
|
January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
Anthony D Sung, Thuy Koll, Shannon H Gier, et al.
The New England Journal of Medicine
|
October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
JAMA Oncology
|
February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial
Anand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Nature Communications
|
September 18, 2024
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia
Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, et al.
Future Oncology (London, England)
|
July 11, 2026
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed <i>FLT3</i>-ITD-negative acute myeloid leukemia
Pau Montesinos, Jessica K Altman, Lars Bullinger, et al.
Haematologica
|
August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
Sabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
The Lancet. Oncology
|
June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E Perl, Jessica K Altman, Jorge Cortes, et al.
American Journal of Hematology
|
January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
American Journal of Hematology
|
June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Transplantation and Cellular Therapy
|
January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
Anthony D Sung, Thuy Koll, Shannon H Gier, et al.
The New England Journal of Medicine
|
October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Page
of 9